RSS for Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancerhttp://academic.research.microsoft.com/Rss.aspx?cata=9&id=29539271Search RSS feed for Microsoft Academic SearchMSRA Libra RSS Burner(c)2008 Microsoft Corpration, All right reserved.Fri, 24 May 2013 06:15:32 GMTFri, 24 May 2013 06:15:32 GMTCarboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancerhttp://academic.research.microsoft.com/Publication/29539271Thu, 23 May 2013 23:15:32 GMT295392712Stephanie Jeske, Scott T. Tagawa, Olugbenga Olowokure, Jodi Selzer, Paraskevi Giannakakou, David M. Nanus: (Citations:2)view publication
ObjectivesDocetaxel is considered first-line chemotherapy for patients with metastatic castrate resistant prostate cancer (CRPC). Carboplatin and paclitaxel have demonstrated activity in CRPC but published data are limited regarding use after docetaxel.
Journal: Urologic Oncology-seminars and Original Investigations, vol. 29, no. 6, pp. 676-681, 2011
]]>